https://www.selleckchem.com/pr....oducts/Rapamycin.htm
In vitro and ex vivo, AAT reduced primary granule release and the described plasma membrane variance was resolved post AAT augmentation therapy in vivo, the effects of which significantly altered the AATD neutrophil membrane proteome to that of a non-AATD COPD cell.These results provide strong insight into the mechanism of neutrophil driven airways disease associated with AATD. Therapeutic AAT augmentation modified the membrane proteome to that of a typical COPD cell, with implications for clinical practice. Copyright ©ERS 2020.In res
Like
Comment
Share
